Acorda shares soar on possible patent extension of MS drug

BOSTON/BANGALORE Fri Apr 15, 2011 3:32am IST

Related Topics

Stocks

   

BOSTON/BANGALORE (Reuters) - Shares of Acorda Therapeutics Inc jumped 27 percent before being halted amid optimism the company will be granted a patent extension on its multiple sclerosis drug Ampyra.

The U.S. Patent and Trademark Office issued an update on its website titled "reasons for allowance" of Acorda's "828 " patent application.

Robert W. Baird & Co analyst Christopher Raymond , who termed the event as a "nice surprise , " said the patent extension will push the timeline of generic Ampyra launch beyond 2024.

"(Acorda) management is still waiting for confirmation from USPTO that a formal allowance is forthcoming , " Raymond , who raised his price target on the stock to $30 from $27 , said .

A spokesman for Acorda said the company has seen the USPTO update but declined to comment further.

According to Mark Schoenebaum, an analyst at ISI Group, the update "suggests the organization will grant the patent, but we are still working through the details."

Ampyra was approved by the U.S. Food and Drug Administration on January 22, 2010 and has

seven years of exclusivity in multiple sclerosis based on its orphan drug status.

The patent, if extended through to 2024, would be worth at least $10 a share, according to Michael Yee, an analyst at RBC Capital Markets.

Analysts see Ampyra reaching sales of around $871 million by 2015, according to Thomson Pharma consensus forecasts.

"We believe that IP (intellectual property) extension would be a significant catalyst for the shares and would make Acorda much more amenable to be an acquisition target," Yee said.

Acorda shares rose $5.71 to $27.13 before being halted on the Nasdaq stock market.

(Reporting by Toni Clarke in Boston and Anand Basu in Bangalore; editing by John Wallace)

FILED UNDER:

Fighting Ebola

Reuters Showcase

Reuters Poll

Reuters Poll

Oil price will average less in 2015 than during financial crisis - Reuters Poll.  Full Article 

Stake Sale

Stake Sale

Strong demand for Coal India boosts privatisation drive.  Full Article 

New Italy President

New Italy President

Italy elects senior judge Sergio Mattarella as president.  Full Article 

Pharma Deal

Pharma Deal

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy  Full Article 

SpiceJet Bailout

SpiceJet Bailout

SpiceJet board approves up to $243 mln share sale plan  Full Article 

AirAsia Jet Crash

AirAsia Jet Crash

AirAsia captain left seat before jet lost control - sources  Full Article 

India Art Fair

India Art Fair

Art fair turns India's capital into art hub.  Full Article 

Movie Review

Movie Review

"Rahasya" is an ode to Agatha Christie.  Full Article 

Review: Hawaizaada

Review: Hawaizaada

Movie Review: Hawaizaada  Full Article | Related Story 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage